Circadian Regulation of Hippocampal Long-Term Potentiation

Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, California 90024-1759, USA.
Journal of Biological Rhythms (Impact Factor: 2.77). 07/2005; 20(3):225-36. DOI: 10.1177/0748730405276352
Source: PubMed


The goal of this study is to investigate the possible circadian regulation of hippocampal excitability and long-term potentiation (LTP) measured by stimulating the Schaffer collaterals (SC) and recording the field excitatory postsynaptic potential (fEPSP) from the CA1 dendritic layer or the population spike (PS) from the soma in brain slices of C3H and C57 mice. These 2 strains of mice were of interest because the C3H mice secrete melatonin rhythmically while the C57 mice do not. The authors found that the magnitude of the enhancement of the PS was significantly greater in LTP recorded from night slices compared to day slices of both C3H and C57 mice. They also found significant diurnal variation in the decay of LTP measured with fEPSPs, with the decay slower during the night in both strains of mice. There was evidence for a diurnal rhythm in the input/output function of pyramidal neurons measured at the soma in C57 but not C3H mice. Furthermore, LTP in the PS, measured in slices prepared during the day but recorded during the night, had a profile remarkably similar to the night group. Finally, PS recordings were carried out in slices from C3H mice maintained in constant darkness prior to experimentation. Again, the authors found that the magnitude of the enhancement of the PS was significantly greater in LTP recorded from subjective night slices compared to subjective day slices. These results provide the 1st evidence that an endogenous circadian oscillator modulates synaptic plasticity in the hippocampus.

Download full-text


Available from: Christopher S Colwell, Dec 12, 2013
    • "The presence of melatonin receptors in the SCN describes its direct action where, together with serotonin (via 5-HT 2C receptors), it establishes the biorhythms of the master clock that in turn modifies brain stem monoamine release. Its presence in other limbic brain regions suggests a central role for melatonin in circadian regulation of regional brain function, such as hippocampal plasticity (Chaudhury et al., 2005) and the circadian pattern of clock gene expression in hippocampal neurons (Wakamatsu et al., 2001; Jilg et al., 2010). Both MT 1 and MT 2 receptors are 7-trans- membrane, G protein-coupled receptors acting via Gi proteins (Tardito et al., 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective Antidepressants are at best 50–55% effective. Non-compliance and the antidepressant discontinuation syndrome (ADS) are causally related yet poorly appreciated. While ADS is associated with most antidepressants, agomelatine seems to be devoid of such risk. We review the neurobiology and clinical consequences of antidepressant non-compliance and the ADS. Agomelatine is presented as a counterpoint to learn more on how ADS risk is determined by pharmacokinetics and pharmacology.DesignThe relevant literature is reviewed through a MEDLINE search via PubMed, focusing on agomelatine and clinical and preclinical research on ADS.ResultsAltered serotonergic dysfunction appears central to ADS so that how an antidepressant targets serotonin will determine its relative risk for inducing ADS and thereby affect later treatment outcome. Low ADS risk with agomelatine versus other antidepressants can be ascribed to its unique pharmacokinetic characteristics as well as its distinctive actions on serotonin, including melatonergic, monoaminergic and glutamatergic-nitrergic systems.Conclusions This review raises awareness of the long-term negative aspects of non-compliance and inappropriate antidepressant discontinuation, and suggests possible approaches to “design-out” a risk for ADS. It reveals intuitive and rational ideas for antidepressant drug design, and provides new thoughts on antidepressant pharmacology, ADS risk and how these affect long-term outcome. Copyright © 2014 John Wiley & Sons, Ltd.
    No preview · Article · Nov 2014 · Human Psychopharmacology Clinical and Experimental
  • Source
    • "However, it is unclear how its rhythmic expression leads to such behavioral changes. Vesicle transporter activity throughout the brain (Darna et al., 2009) and changes in hippocampal synaptic plasticity (Chaudhury et al., 2005) exhibit diurnal variations; similarly, modulation of neurotransmitter function by the circadian clock provide potential ways through which circadian molecular mechanisms may be translated into diurnal electrophysiological and behavioral changes. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Circadian rhythms modulate behavioral processes over a 24h period through clock gene expression. What is largely unknown is how these molecular influences shape neural activity in different brain areas. The clock gene Per2 is rhythmically expressed in the striatum and the cerebellum and its expression is linked with daily fluctuations in extracellular dopamine levels and D2 receptor activity. Electrophysiologically, dopamine depletion enhances striatal local field potential (LFP) oscillations. We investigated if LFP oscillations and synchrony were influenced by time of day, potentially via dopamine mechanisms. To assess the presence of a diurnal effect, oscillatory power and coherence were examined in the striatum and cerebellum of rats under urethane anesthesia at four different times of day (ZT1, 7, 13 and 19 – indicating number of hours after lights turned on in a 12h:12h light-dark cycle). We also investigated the diurnal response to systemic raclopride, a D2 receptor antagonist. Time of day affected the proportion of LFP oscillations within the 0-3 Hz band and the 3-8 Hz band. In both the striatum and the cerebellum, slow oscillations were strongest at ZT1 and weakest at ZT13. A 3-8 Hz oscillation was present when the slow oscillation was lowest, with peak 3-8 Hz activity occurring at ZT13. Raclopride enhanced the slow oscillations, and had the greatest effect at ZT13. Within the striatum and with the cerebellum, 0-3 Hz coherence was greatest at ZT1, when the slow oscillations were strongest. Coherence was also affected the most by raclopride at ZT13. Our results suggest that neural oscillations in the cerebellum and striatum, and the synchrony between these areas, are modulated by time of day, and that these changes are influenced by dopamine manipulation. This may provide insight into how circadian gene transcription patterns influence network electrophysiology. Future experiments will address how these network alterations are linked with behavior.
    Full-text · Article · Sep 2014 · Frontiers in Systems Neuroscience
  • Source
    • "compared with control. Scale bar 0 100 μm al. 1999; Bova et al. 1998), 5-HT 2C receptor mRNA expression , glucocorticoid receptor and mineralocorticoid receptor mRNA expression (Holmes et al. 1995, 1997), the responsiveness of pyramidal cells to norepinephrine, acetylcholine, and 5-HT (Brunel and de Montigny 1987), the activity of mitogen-activated protein kinase and cyclic adenosine monophosphate (Eckel-Mahan et al. 2008), and hippocampal excitability and long-term potential (Chaudhury et al. 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Rationale: Circadian disturbances are strongly linked with major depression. The circadian proteins CLOCK and BMAL1 are abundantly expressed but function differently in the suprachiasmatic nucleus (SCN) and hippocampus. However, their roles in depressive-like behavior are still poorly understood. Objectives: To investigate the alterations of CLOCK and BMAL1 in the SCN and hippocampus in rats subjected to chronic unpredictable stress (CUS) and to explore the relationship of circadian protein and the depressive-like behavior. Results: Together with depressive-like behavior induced by CUS, CLOCK and BMAL1 in the SC were inhibited during the light period, and the peak expression of CLOCK in the hippocampus was shifted from the dark to light period. BMAL1 expression in the hippocampus was not significantly changed. Two weeks after the termination of CUS, abnormalities of CLOCK in the CA1 and CA3 endured, with unchanged depressive-like behavior, but the expression of CLOCK and BMAL1 in the SCN recovered to control levels. Knockdown of the Clock gene in CA1 induced depressive-like behavior in normal rats. CLOCK in the SCN and hippocampus may participate in the development of depressive-like behavior. However, CLOCK in the hippocampus but not SCN was involved in the long-lasting effects of CUS on depressive-like behavior. BMAL1 in the hippocampus appeared to be unrelated to the effects of CUS on depressive-like behavior. Conclusion: CLOCK protein in the hippocampus but not SCN play an important role in the long-lasting depressive-like behavior induced by CUS. These findings suggest a novel therapeutic target in the development of new antidepressants focusing on the regulation of circadian rhythm.
    Full-text · Article · Dec 2012 · Psychopharmacology
Show more